Ayala Pharmaceuticals Inc (ADXS)

[Meishairwin]

Complaints about "Dilution Dan" make no sense to me. This company needs funds to develop its products, which seem to be progressing quite well. So, no problem with the use of funds. There's only two places to get funds (typically): secondary offerings and partnership deals. BOTH "dilute" current shareholders. So, unless you want ADXS to stop developing its drugs, you have to accept one type of dilution or the other. That's SOP for early stage biotechs. The ONLY issue is: whether a specific dilutive event has the best price associated with it compared to what else is available. On that question NO ONE here is knowledgeable enough to offer analysis to clearly demonstrate Dan is doing a poor job. Since we have no idea what kinds of partnership deals are possible on what terms, there's no way for us retail folks to have a clue on this question, except indirect and qualitative.

Given that he is highly experienced in deals before becoming ADXS CEO, my guess is he knows what he's doing. Some of the deals he has made sound very efficient to me (e.g., Korea, South America, GOG, India). That is my indirect and qualitative assessment. Anyone got better? And the fact that the current share price is lower than average secondary price means nothing because we're a long way from monetization.

If you can offer detailed financial analysis to demonstrate Dan's dilution has been inefficient and poorly considered, bring it forward. Otherwise, stop whining.